1. To find out the role of CYFRA 21-1 in diagnosis of lung cancer 2.To find out the sensitivity and specificity of CYFRA 21-1 and CEA levels in lung carcinoma 3. To find out CYFRA 21-1 levels after treatment of lung cancer.
A total of 78 patients were taken including 58 cases and 20 controls. All cases with histopathological proven lung carcinoma and with proper staging were included in the study. CEA was measured using UBI MAGIWELL CEA CM-201 kit and CYFRA 21-1 was measured using ECLIA kit manufactured by Roche diagnostics USA. The statistical analysis was done using t-test, ANOVA and post hoc analysis.
Using a threshold value of 3.0 ng/ml for CYFRA 21-1, sensitivity and specificity, were 90.1% and 90.0% respectively whereas for CEA with threshold value of 3.0 ng/ml for non smokers and 5.0 ng/ml for smokers, sensitivity and specificity were 44.9% and 75.0% respectively. The sensitivity of tumor markers for squamous cell, adenocarcinoma and small cell carcinoma was 96%, 80% and 70.4% respectively for CYFRA 21-1. In eleven patients both pre-treatment levels as well as levels after receiving first cycle of chemo radiotherapy were assessed. Six patients showed more than 35% reduction in the CYFRA21-1 levels after treatment. Out of four patients in whom levels did not fall 3 patients expired within three months. Three out of six former group patients are still following after one year of treatment.
CYFRA 21–1 is a sensitive and specific marker for lung carcinoma. CEA can be used as a tumor marker in lung carcinoma but it is inferior to CYFRA 21–1 in diagnosing lung carcinoma especially squamous cell type. Patents showing a decline in CYFRA 21–1 levels after treatment have better survival.
Cyfra 21-1 can be used for diagnosis of advavaced squamous cell lung cancer.Declining levels of cyfra 21-1 can determine the survivil of lung cancer after treatment.
Showkat Mufti, No Financial Disclosure Information; No Product/Research Disclosure Information